The Outcomes of Concomitant Radiation Plus Temozolomide ... - NCI

Hanan Shawky, et al. 117
carmustine, procarbazine, and high-dose
methylprednisolone as additions to surgery and
radiotherapy for the treatment of malignant glioma.
Cancer Treat Rep. 1983, 67: 121-32.
22- Stupp R, Hegi ME. Recent developments in the
management of malignant glioma. In: Perry MC, ed.
ASCO 2003 educational book. Alexandria, Va.:
American Society of Clinical Oncology. 2003, 779-
88.
23- Stupp R, Hegi ME, Mason WP, van den Bent MJ,
Taphoorn MJ, Janzer RC, et al. Effects of Radiotherapy
with Concomitant and Adjuvant Temozolomide versus
Radiotherapy alone on survival in Glioblastoma in
a Randomized Phase III study: 5-year Analysis of the
EORTC-NCIC trial. The Lancet Oncology. 2009, 10
(5): 459-66.
24- Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke
B, Kortmann R-D, et al. Phase II Trial of Lomustine
Plus Temozolomide Chemotherapy in Addition to
Radiotherapy in Newly Diagnosed Glioblastoma:
UKT-03. J. Clin. Oncol. 2006, 24 (27): 4412-7.
25- Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten
M, Blaschke B, et al. Efficacy and Tolerability of
Temozolomide in an Alternating Weekly Regimen in
Patients With Recurrent Glioma. J. Clin. Oncol. 2007,
25 (22): 3357-61.
26- Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas
DC, Doherty L, et al. Phase II study of temozolomide,
thalidomide, and celecoxib for newly diagnosed
glioblastoma in adults. Neuro Oncol. 2008, 10:
300-8.
27- Wakabayashi T, Kayama T, Nishikawa R, Takahashi
H, Yoshimine T, Hashimoto N, et al. A Multicenter
Phase I Trial of Interferon-{beta} and Temozolomide
Combination Therapy for High-grade Gliomas
(INTEGRA Study). Jpn. J. Clin. Oncol. 2008, 38:
715-8.
28- Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle
KA, Uhm JH, et al. Phase I/II Trial of Erlotinib and
Temozolomide With Radiation Therapy in the
Treatment of Newly Diagnosed Glioblastoma
Multiforme: North Central Cancer Treatment Group
Study N0177 J. Clin. Oncol. 2008, 26: 5603-9.
29- Prados MD, Chang SM, Butowski N, DeBoer R,
Parvataneni R, Carliner H, et al. Phase II Study of
Erlotinib Plus Temozolomide During and After
Radiation Therapy in Patients With Newly Diagnosed
Glioblastoma Multiforme or Gliosarcoma. J. Clin.
Oncol. 2009, 27: 579-84.
30- van den Bent MJ, Brandes AA, Rampling R,
Kouwenhoven MCM, Kros JM, Carpentier AF, et al.
Randomized Phase II Trial of Erlotinib Versus
Temozolomide or Carmustine in Recurrent
Glioblastoma: EORTC Brain Tumor Group Study
26034. J. Clin. Oncol. 2009, 27: 1268-74.
31- Glas M, Happold C, Rieger J, Wiewrodt D, Bahr O,
Steinbach JP, et al. Long-Term Survival of Patients
With Glioblastoma Treated With Radiotherapy and
Lomustine Plus Temozolomide. J. Clin. Oncol. 2009,
27: 1257-61.
32- Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-
Schughart L A, Leukel P, et al. Temozolomide
Preferentially Depletes Cancer Stem Cells in
Glioblastoma. Cancer Res. 2008, 68: 5706-15.
33- Newlands ES, Blackledge GR, Slack JA, Rustin GJ,
Smith DB, Stuart NS, et al. Phase I trial of
temozolomide (CCRG 81045: M&B 39831: NSC
362856). Br J Cancer. 1992, 65: 287-91.
34- Marzolini C, Decosterd LA, Shen F, Gander M,
Leyvraz S, Bauer J, et al. Pharmacokinetics of
temozolomide in association with fotemustine in
malignant melanoma and malignant glioma patients:
Comparison of oral, intravenous, and hepatic intraarterial
administration. Cancer Chemother Pharmacol.
1998, 42: 433-40.
35- Stupp R, Ostermann S, Leyvraz S, Csajka C, Buclin
T. Cerebrospinal fluid levels of temozolomide as a
surrogate marker for brain penetration. Proc Am Soc
Clin Oncol. 2001, 20: 59a, (abstr 232).
36- Brock CS, Newlands ES, Wedge SR, Bower M, Evans
H, Colquhoun I, et al. Phase I trial of temozolomide
using an extended continuous oral schedule. Cancer
Res. 1998, 58: 4363-7.
37- Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond
LA, Patnaik A, et al. Marked inactivation of O6-
alkylguanine-DNA alkyltransferase activity with
protracted temozolomide schedules. Br J Cancer.
2003, 88: 1004-11.
38- Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller
M, et al. Correlation of O6-Methylguanine
Methyltransferase (MGMT) Promoter Methylation
With Clinical Outcomes in Glioblastoma and Clinical
Strategies to Modulate MGMT Activity. J. Clin.
Oncol.2008, 26 (25): 4189-99.
39- Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession
A, Tallini G, et al. MGMT Promoter Methylation
Status Can Predict the Incidence and Outcome of
Pseudoprogression After Concomitant
Radiochemotherapy in Newly Diagnosed Glioblastoma
Patients. J. Clin. Oncol. 2008, 26 (13): 2192-7.
40- Esteller M, Garcia-Foncillas J, Andion E, Goodman
SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of
the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 2000,
343: 1350-4. [Erratum, N Engl J Med. 2000, 343:
1740].
41- Hegi ME, Diserens AC, Godard S, Dietrich P-Y, Regli
L, Ostermann S, et al. Clinical trial substantiates the
predictive value of O-6-methylguanine-DNA
methyltransferase promoter methylation in
glioblastoma patients treated with temozolomide. Clin
Cancer Res. 2004, 10: 1871-4.
42- Chakravarti A, Erkkinen MG, Nestler U, Stupp R,
Mehta M, Aldape K, et al. Temozolomide-Mediated
Radiation Enhancement in Glioblastoma: A Report
on Underlying Mechanisms. Clin. Cancer Res. 2006,
12 (15): 4738-46.
43- Stupp R, Dietrich P-Y, Ostermann Kraljevic S, Pica
A, Maillard I, Maeder P, et al. Promising survival for